NCT00625469 - Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan | Biotech Hunter

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions

Pulmonary Arterial HypertensionIdiopathic Pulmonary Fibrosis

Interventions

DRUG

bosentan

62.5mg orally bid for first month, followed by 125mg bid thereafter

Trial Locations (2)

David Geffen School of Medicine UCLA, Los Angeles

Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA, Los Angeles